Commentary Open Access

Pandemic has Played Havoc Beyond Imagination

Abstract

COVID-19 is a newly developed disease caused by a novel coronavirus, SARS-CoV2 that leads to adverse pulmonary pathological features [1]. COVID-19 is a pandemic with 2,72,36,916 confirmed cases worldwide and 8,91,031deaths, as on September 08th, 2020 [2]. CVDs remain to be one of the major causes of death globally. The CVD patients, suffering from COVID-19 could not attract proper attention. COVID-19 leads to severity in patients with CVDs as it interacts with the cardiovascular system on various levels, thereby, deteriorating the diseased conditions and thus, leading to myocardial injury and dysfunction [1]. As, it has been clearly revealed, that the spike protein of SARS-CoV-2 aids in the entry of the virus inside the cell via human ACE2 receptors present on the surface of epithelial cells of lung and other tissues [3], it can be hypothesized that the levels of ACE2 are associated with SARSCoV-2 infection susceptibility. However, various studies have found that ACE inhibitor improves the clinical outcome of COVID-19 patients with hypertension and continuation of these medicines is beneficial [4,5]. It has also been documented that the cellular ACE2 levels are not same in all individuals and hence, polymorphisms of ACE2 may have effect on its varying levels [6].

Shruti Sharma*

To read the full article Download Full Article